ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
ASP Isotopes Inc

ASP Isotopes Inc (ASPI)

3.215
-0.275
(-7.88%)
At close: 18 July 6:00AM
3.22
0.005
( 0.16% )
After Hours: 6:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.22
Bid
3.20
Offer
3.32
Volume
1,441,746
3.05 Day's Range 3.43
0.58 52 Week Range 5.67
Market Cap
Previous Close
3.49
Open
3.42
Last Trade Time
06:00:00
Financial Volume
US$ 4,573,923
VWAP
3.1725
Average Volume (3m)
959,582
Shares Outstanding
51,762,833
Dividend Yield
-
PE Ratio
-10.24
Earnings Per Share (EPS)
-0.31
Revenue
433k
Net Profit
-16.29M

About ASP Isotopes Inc

ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of urani... ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida. Show more

Sector
Chemicals & Chem Preps, Nec
Industry
Chemicals & Chem Preps, Nec
Headquarters
Wilmington, Delaware, USA
Founded
1970
ASP Isotopes Inc is listed in the Chemicals & Chem Preps sector of the NASDAQ with ticker ASPI. The last closing price for ASP Isotopes was US$3.49. Over the last year, ASP Isotopes shares have traded in a share price range of US$ 0.58 to US$ 5.67.

ASP Isotopes currently has 51,762,833 shares in issue. The market capitalisation of ASP Isotopes is US$180.65 million. ASP Isotopes has a price to earnings ratio (PE ratio) of -10.24.

ASPI Latest News

ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced the closing of the previously announced underwritten public...

ASP Isotopes Announces Pricing of Public Offering of Common Stock

WASHINGTON, July 12, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced the pricing of the previously announced underwritten public...

ASP Isotopes Announces Proposed Public Offering of Common Stock

WASHINGTON, July 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced that it has commenced an underwritten public offering of shares of...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10.134.20711974113.093.972.8121584063.55585035CS
4-0.28-83.53.972.8113839543.33501902CS
12003.225.672.819595823.89967911CS
261.476.92307692311.825.671.76027803643.73107991CS
522.61427.8688524590.615.670.585056773.1864001CS
156003.225.670.283938182.65434496CS
260003.225.670.283938182.65434496CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMBCambium Bio Ltd
AUD 0.40
(9,900.00%)
2k
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M
VPRVolt Group Ltd
AUD 0.002
(100.00%)
343.18k
TD1Tali Digital Limited
AUD 0.0015
(50.00%)
10k
PRXProdigy Gold NL
AUD 0.003
(50.00%)
1.47M
RHYORhythm Biosciences Limited
AUD 0.005
(-75.00%)
916
JTLJayex Technology Limited
AUD 0.001
(-50.00%)
1.34M
EDEEden Innovations Ltd
AUD 0.001
(-50.00%)
79k
DTIDTI Group Limited
AUD 0.009
(-35.71%)
4.16k
SI6Si6 Metals Limited
AUD 0.002
(-33.33%)
2.8M
ATHAlterity Therapeutics Ltd
AUD 0.007
(40.00%)
154.34M
AMDArrow Minerals Limited
AUD 0.003
(20.00%)
123.6M
FBRFBR Limited
AUD 0.05
(4.17%)
64.55M
MRQOMRG Metals Limited
AUD 0.001
(0.00%)
43.5M
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M

ASPI Discussion

View Posts
kairos kairos 1 week ago
ASPI Bottom may be in and Uranium stocks of fire today ... grabbed some

👍️0
BeingReal BeingReal 2 months ago
Who is the largest competition for ASPI? What is the next catalyst?
👍️0
kairos kairos 2 months ago
Sure is moving nicely, getting a little toppy on the chart with this big move ...

👍️0
IPO$ IPO$ 2 months ago
Nice CNBC ad today.
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ASPI...BREAK OU!!!
👍️0
kairos kairos 3 months ago
Still holding a bunch. What a beauty. Nuclear power a great place to be
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
THE BEST STOCKS YOU WILL NEVER SEE IHUBBERS TALK ABOUT BECAUSE THEY FOLLOW OTHERS TO FIND TRADES
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ASPI...4.50 NEXT STOP!!!!
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ASPI...A TRUE BLUE SKY BREAK OUT SET UP...MONSTER IN THE MAKING!
👍️0
realtmg realtmg 5 months ago
Trash… You were warned
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ASPI...WAHT A CLOSE 4 BUCKS!!
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
HERE WE GO...END OF DAY SMASH!!!!
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ASPI...MONSTER IN THE MAKING...ONE OF A KIND COMPANY!!!
👍️0
FlyingDutchman FlyingDutchman 5 months ago
few ticks more and ind it will be a DB top pos..tt
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ASPI...BREAK OUT WEEKLY....BEAUTY SET UP!
👍️0
kairos kairos 5 months ago
beauty move so far ...

👍️0
Monksdream Monksdream 5 months ago
ASPI new 52 week high
👍️0
kairos kairos 7 months ago
I'm a buyer at these levels
👍️0
Mktman2024 Mktman2024 7 months ago
Wainwright 3.25 target is way off the mark ...This technology will open huge markets for ASP Isotopes during 2024 projecting future revenues with further offtake agreements and JVs.during 2024-2025
👍️0
kairos kairos 8 months ago
That's an impressive first and only post. Sorry I missed this one earlier but suspect I will be buying some on any dips
👍️0
BlazingStocks BlazingStocks 10 months ago
$ASPI - Little-Known Company Sets Sights On 800+% Potential Growth In Future $125Bn Quantum Computing Market, Potential Target For Industry Giants Google, Microsoft, Intel, And IBM…
https://www.tgd8hjs.com/3J67C1/4ZKJNX3/
👍️0
smallcapbigmoney smallcapbigmoney 1 year ago
$ASPI Future looks bright. Hitting $500 million market with two new plants and a contract for Carbon-14 production which currently has no competitors. Great time to buy
👍️0
Invest-in-America Invest-in-America 1 year ago
ASPI: Pressure building-up in the A.H., as I post this (32% UP). Could we have some type of 'isotopic' nuclear reaction transpiring here??? (Get the pun??)

👍️0
TheFinalCD TheFinalCD 2 years ago
back to 2.26 what a yo-yo
👍️0
jedijazz jedijazz 2 years ago
$ASPI #Shortages of global supplies of molybdenum-99 (Mo-99) and lutetium-177 (Lu-177) may be inevitable.

MAJOR ADVANTAGES OF PRODUCTION OF ISOTOPES by ASP



FACT: There are only five nuclear reactors in the world capable of producing the Mo-99, an isotope used to produce technetium-99 (Tc-99m). Tc-99m is used in approximately 50,000 diagnostic medical procedures every day in the U.S. for advanced diagnostic imaging tests and limits in production directly impact patient care and access.

https://aspisotopes.com/medical-isotopes/
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI 5,352 views- ASP Isotopes is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with both low and high atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The company believes that its technology has a low capital cost and is extremely environmentally friendly. The company's first commercial product will be Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market.

ASP Isotopes: Creating a Brighter, Cleaner Future for Isotope Production via @YouTube
👍️0
jedijazz jedijazz 2 years ago
NEWS: ASP Isotopes Inc. Recognizes the Current Mo-99 Shortages and Continues to Execute on Plans to Help Ease Supply Chain Issues before 2024
Monday, November 21, 2022 8:45 AM

Company Update
BOCA RATON, FL / ACCESSWIRE / November 21, 2022 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today confirmed that we remain on track to achieve our planned production of commercial quantities of highly enriched Molybdenum-100 before 2024. The Company plans to offer highly enriched Mo-100 to be used in the production of either technetium-99m (Tc-99m) or Mo-99 in a cyclotron or in a linear accelerator. Mo-99 is the active ingredient for Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures to diagnose heart disease and cancer, to study organ structure and function, and to perform other important medical applications.

On November 17, 2022, the U.S. Food and Drug Administration (FDA) placed Tc-99m Sodium Pertechnetate generators on the Drug Shortages List. The Company has previously recognized the Mo-99 supply chain challenges in the existing medical isotope market. Currently, several overseas reactors that produce Mo-99, which is used to produce Tc-99m, are offline. The Mo-99 supply chain has historically been fragile and remains so today. The Company also understands that several ex-US consumers of Mo-99 are currently without supply, due to these supply issues. More information regarding the availability of Tc-99m generators is available on the FDA Drug Shortages List (https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm).

The Company's molybdenum enrichment facility, currently under construction in Pretoria, South Africa is designed to have capacity to produce greater than 20 Kg/ year of molybdenum enriched to >95% in the Mo-100 isotope. The Company continues to expect that this facility will enter commercial production before 2024. The Company is in commercial discussions with multiple potential customers in multiple regions, with anticipated demands that currently exceed four times the headline capacity of the plant during the first five years of proposed production. The Company plans to expand capacity to meet the demands of these potential customers and update investors with the actual production capacity of the facility during 1H 2023 when the plant is expected to enter the commissioning phase.

About ASP Isotopes Inc.

ASP is an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.

Our initial focus is on the production and commercialization of enriched Molybdenum-100 ("Mo-100"), and we are constructing a first commercial-scale Mo-100 enrichment plant located in South Africa. We believe that the Mo-100 we may develop using the ASP technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

We may also seek to use the ASP technology to separate Silicon-28, which we believe has potential application in the quantum computing target end market, and Carbon-14, which we believe has potential application in the pharma/agrochemical target end market. In addition, we are considering future development of the ASP technology for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.

We were incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is www.aspisotopes.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended and the Securities Litigation Reform Act of 1995. The Company may also make written or oral "forward-looking statements" in documents filed with the U.S. Securities and Exchange Commission, in press releases, in reports to stockholders and in other materials or communications describing the Company. These "forward-looking statements" involve a number of risks, uncertainties, assumptions and other factors, many of which are outside of the Company's control, that could cause actual results to differ materially from such statements. For a more detailed description of these risks, uncertainties, assumptions and other factors, please see the Company's filings with the Securities and Exchange Commission, (and in particular the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company's SEC filings). Readers are cautioned not to put undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date they are made, and we have no intention and undertake no obligation to update or revise any of them in light of new information, future events or otherwise. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Robert Ainscow - Interim Chief Financial Officer
ir@aspisotopes.com

Dave Gentry - RedChip
dave@redchip.com

SOURCE: ASP Isotopes Inc.
👍️0
jedijazz jedijazz 2 years ago
$ASPI ASP Isotopes had said before that they had signed a letter of intent for five times the productive capacity of the first plant. That would be 20 million in revenue and 16m in gross profit. They have stated before that because of the large return on investment, they plan on reinvesting proceeds into additional capacity.
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI chart looks like it has formed a support base and is ready to start an uptrend
👍️0
jedijazz jedijazz 2 years ago
New Video out! ASP Isotopes: Disrupting Clean Tech in a Multi-Billion Dollar Industry http://ow.ly/QSrh50LHqOm

#NASDAQ: $ASPI
👍️0
jedijazz jedijazz 2 years ago
Huge Potential here on Shortage of TC-99m $ASPI

https://www.youtube.com/watch?v=ht23S8zx_sI
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI Mo-99/Tc-99m shortage expected to impact provider care and limit patient access October 31, 2022 https://t.co/bULuWd5HFj



$ASPI Medical Isotopes: https://aspisotopes.com/medical-isotopes/
👍️0
budfoxfun budfoxfun 2 years ago
Bullish! $ASPI CEO Acquired 35k shares @ $4 https://sec.gov/Archives/edgar/data/1921865/000121390022072582/xslF345X03/ownership.xml
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI NEWS: ASP Isotopes Inc. Announces Closing of Initial Public Offering and Nasdaq Listing
Tuesday, November 15, 2022 2:00 PM
Topic:
IPO
BOCA RATON, FL / ACCESSWIRE / November 15, 2022 / ASP Isotopes Inc. ("ASPI" or the "Company") (Nasdaq:ASPI), an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.

The shares began trading on the Nasdaq Capital Market LLC on November 10, 2022, under the ticker symbol "ASPI."

The Company intends to use the net proceeds of the offering for the completion of its Molybdenum enrichment facility in Pretoria, South Africa and other general corporate purposes.

Revere Securities LLC is acted as sole book-running manager for the offering

A registration statement on Form S-1 (File No. 333-267392), is filed with the Securities and Exchange Commission ("SEC") and was declared effective on November 9, 2022. The final prospectus relating to the offering is available on the SEC's website at http://www.sec.gov . Electronic copies of the final prospectus relating to this offering are also available, from: Revere Securities LLC, 650 5th Ave, New York, NY 10019, United States.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ASP Isotopes Inc.

ASPI is an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.

Our initial focus is on the production and commercialization of enriched Molybdenum-100 ("Mo-100"), and are constructing a first commercial-scale Mo-100 enrichment plant located in South Africa. We believe that the Mo-100 we may develop using the ASP technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

We may also seek to use the ASP technology to separate Silicon-28, which we believe has potential application in the quantum computing target end market, and Carbon-14, which we believe has potential application in the pharma/agrochemical target end market. In addition, we are considering future development of the ASP technology for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.

We were incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is www.aspisotopes.com.

Forward Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts
Robert Ainscow - Chief Financial Officer
ir@aspisotopes.com

Dave Gentry - RedChip
dave@redchip.com

SOURCE: ASP Isotopes
👍️ 1
jedijazz jedijazz 2 years ago
Great opportunity here with $ASPI https://fintel.io/s/us/aspi
👍️0
jedijazz jedijazz 2 years ago
$ASPI Daily trades: https://ih.advfn.com/stock-market/NASDAQ/asp-isotopes-ASPI/trades
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI ASP Isotopes: Leading the Way with Game-Changing Isotope Production Tech... via @YouTube
👍️ 1
jedijazz jedijazz 2 years ago
ASPI Share Price and News / ASP Isotopes Inc (NASDAQ)
https://fintel.io/s/us/aspi
👍️ 1
jedijazz jedijazz 2 years ago
$ASPI #IPO #Nasdaq "ASP Isotopes Inc. Announces Pricing of Initial Public Offering and Nasdaq Listing"
-ASP Isotopes
Thu, November 10, 2022 at 7:30 AM

BOCA RATON, FL / ACCESSWIRE / November 10, 2022 / ASP Isotopes Inc. ("ASPI" or the "Company") (NASDAQ:ASPI), an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. In addition, ASPI has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

The shares are expected to begin trading on the Nasdaq Capital Market LLC on November 10, 2022, under the ticker symbol "ASPI" and the offering is expected to close on or about November 14, 2022, subject to satisfaction of customary closing conditions.

Revere Securities LLC is acting as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-267392), was filed with the Securities and Exchange Commission ("SEC") and was declared effective on November 9, 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, from: Revere Securities LLC, 650 5th Ave, New York, NY 10019, United States. The final prospectus will also be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ASP Isotopes Inc.

ASPI is an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.

Our initial focus is on the production and commercialization of enriched Molybdenum-100 ("Mo-100"), and are constructing a first commercial-scale Mo-100 enrichment plant located in South Africa. We believe that the Mo-100 we may develop using the ASP technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

We may also seek to use the ASP technology to separate Silicon-28, which we believe has potential application in the quantum computing target end market, and Carbon-14, which we believe has potential application in the pharma/agrochemical target end market. In addition, we are considering future development of the ASP technology for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.

We were incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is www.aspisotopes.com.

Forward Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts
Robert Ainscow - Chief Financial Officer
ir@aspisotopes.com

Dave Gentry - RedChip
dave@redchip.com

SOURCE: ASP Isotopes Inc.

View source version on accesswire.com:
https://www.accesswire.com/724984/ASP-Isotopes-Inc-Announces-Pricing-of-Initial-Public-Offering-and-Nasdaq-Listing
👍️ 1

Your Recent History

Delayed Upgrade Clock